Effect of Chemotherapy Related Hyperglycemia on Bone Marrow Response to Induction Treatment in Children with Acute Lymphoblastic Leukemia

Document Type : Original Article

Authors

1 Department of clinical and chemical pathology, Sohag Faculty of Medicine, Sohag University.

2 Department of Pediatrics, Sohag Faculty of Medicine, Sohag University.

3 Department of Clinical andChemical pathology, Sohag Faculty of Medicine, Sohag University.

4 Department of Clinical and Chemical pathology, Sohag Faculty of Medicine, Sohag University.

5 Department of Clinical and Chemical Pathology, Sohag Oncology Center.

Abstract

background: acute lymphoblastic leukemia (ALL) is a group of hematological neoplasia that accounts for 25% of childhood cancers and up to 75% of childhood leukemia. Hyperglycemia is one of the common side effects of chemotherapy that affects survival rates in adults, aim of this study is to show the effect of chemotherapy-related hyperglycemia on the response to treatment as remission conditions in children with ALL.
Patients and methods: prospective study carried out in the Clinical Pathology Department of Sohag Oncology Center and Sohag University Hospital, on total 109 patients in addition to 20 healthy children as control group the study depends on measuring random blood glucose level before, during and after induction chemotherapy and comparing the response of bone marrow at the end of induction between hyperglycemic patients (random blood glucose ≥200 mg /dl) and euglycemic patients (random blood glucose within normal values).
Results: patients developed hyperglycemia was 33 (30.3%) while patients with euglycemia were 76 (69.7%) and according to the remission state after induction chemotherapy, 99 patients (90.8%) had achieved complete remission state while 10 patients (9.2%) had no remission, 60% of patients with no remission were hyperglycemic during the induction period, and 26 (78,8%) of the 33 hyperglycemic patients aged ≥10years.
Conclusion: hyperglycemia affects the rate of complete remission in ALL children during induction chemotherapy and its incidence
is higher in the age group≥10 years old

 

Main Subjects

References

  1. Munker, R., Hiller, E., Glass, J.chemotherapy-related, and Paquette, R. (2007). Contemporary hematology: Modern hematology –Biology and clinical management. Second Edition. Humana Press, New Jersey, USA. 498pp
  2. Mejía-Aranguré JM, Fajardo-Gutiérrez A, Flores-Aguilar H, Martínez-García MC, Salamanca-Gómez F, Palma-Padilla V, et al (2013): Environmental factors contributing to the development of childhood leukemia in children with Down's syndrome. Leukemia; 17:1905-1907
  3. Bhatia S, Landier W, Hageman L, et al. 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood 2014; 124: 2345-53
  4. Hunger SP, Mullighan CG (2015): Acute Lymphoblastic Leukemia in Children. N Engl J Med 373 (16): 1541-52, 2015
  5. Zhang B, Jian Wang, Hong-Man Xue, Chun Chen, Impact of Chemotherapy-Related Hyperglycemia on Prognosis of Child Acute Lymphocytic Leukemia. Asian Pac J Cancer Prev, 2014, 15 (20), 8855-8859.
  6. Howard SC, Campana D, Coustan-Smith E, et al. Development of a regional flow cytometry center for diagnosis of childhood leukemia in Central America. Leukemia. 2005;19:323–325..
  7. Vu K, Busaidy N, Cabanillas ME, et al (2012). A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk, 12, 355-62.
  8. Roberson JR, Spraker HL, Shelso J, Zhou Y, Inaba H, Metzger ML, et al. Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia. Leukemia.2009;23(2):245–250.
  9. Bochicchio GV, Bochicchio KM, Joshi M, et al (2010). Acute glucose elevation is highly predictive of infection and outcome in critically injured trauma patients. Ann Surg, 252, 597-602.
  10. Maria Moschovi (2018) Hyperglycemia and Diabetes Mellitus in Children with Acute Lymphoblastic Leu­kemia. J Hematol Diabetes 2:1-3.
  11. Banihashem A, Ghasemi A, Ghaemi N, Moazzen N, Amirabadi A. Prevalence of transient hyperglycemia and diabetes mellitus in pediatric patients with acute leukemia. Iranian Journal of Pediatric Hematology-Oncology Vol4.No1. 20 January 2014
  12. Gatzioura I, Papakonstantinou E, Dimitriadou M, Kourti M, SidiV, et al. (2016) Glucose Levels Before the Onset of Asparaginase Predicts Transient Hyperglycemia in Children With Acute Lymphoblastic Leukemia. Pediatr Blood Cancer 63:1181-1184.
  13. Roberson JR, Raju S, Shelso J, et al (2008). Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer, 50, 1207-12.
  14. Lowas SR, Marks D and Malempati S (2009). Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer, 52, 814-8.
  15. Sonabend RY, McKay SV, Okcu M, et al (2009). Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. J Pediatr, 155, 73-8.
  16. Spinola-Castro AM, Siviero-Miachon AA, Andreoni S, et al (2009 Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: an old event revisited. Clin Adv Hematol Oncol, 7, 465-72
  17. Weiser MA, Cabanillas ME, Konopleva M, et al (2004). The relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with hypofractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer, 100, 1179-85

 

 

 

Sohag Medical Journal
Volume 23, Issue 2
April 2019
Pages 197-203

Files

Share

How to cite

Statistics